This is a study of the drug perifosine given in combination with paclitaxel. Perifosine is an
oral anti-cancer agent that has been used in more than 140 people. Paclitaxel is a standard
chemotherapy agent used in many types of cancer. This study is designed to determine the
highest dose of perifosine that can be administered to people every day while they are
receiving paclitaxel in one of two regimens, without severe or prolonged nausea, vomiting and
diarrhea. This study starts with patients taking 50 mg/day and goes up to 150 mg/day.